Madrigal Pharmaceuticals, Inc. (MDGL) delivered a return of 78.89% over the past year. Since MDGL does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Madrigal Pharmaceuticals, Inc. one year ago would be worth $17,889 today, representing a gain of $7,889.

Madrigal Pharmaceuticals, Inc. (MDGL) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For MDGL, the total return equals the price-only return.

Yes, Madrigal Pharmaceuticals, Inc. (MDGL) outperformed the S&P 500 by 53.90 percentage points over the past year. MDGL delivered a total return of 78.89%, compared to the S&P 500's 24.99%. This 53.90pp alpha means investors in MDGL earned more than a passive S&P 500 index fund.

Madrigal Pharmaceuticals, Inc. (MDGL) experienced a maximum drawdown of -29.36% over the past year, declining from its peak on 2025-12-22 to its trough on 2026-03-03. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Madrigal Pharmaceuticals, Inc. (MDGL)'s long-term returns with dividends reinvested. Over 10 years, the total return is 4415.6% (46.4% CAGR) — $10,000 would have grown to $451,561. Over 20 years: 59.0% total return (2.3% CAGR) — $10,000 → $15,897. Over 30 years: 59.0% total return (1.6% CAGR) — $10,000 → $15,897. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Madrigal Pharmaceuticals, Inc.'s best calendar year was 2017 with a total return of 475.1%. Its worst year was 2015 with a total return of -87.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 562.9 percentage points.